Anti-γ-Aminobutyric Acid Type β Receptor Antibody-Associated Encephalitis After 2 Cycles of Durvalumab Therapy in a Patient with Small Cell Lung Cancer: A Case Report
Jiamo Li,1 Jianing Jiang,1,2 Jinyan Lv,1 Ru Zhang,1 Wenting Chen,1,2 Shiyi Li,1 Qianchen Jin,1 Gang Wang1,2 1Department of Medical Oncology, The Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning Province, People’s Republic of China; 2The Key Laboratory of Biomarker, High-Throughpu...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/715ea3d186ce4717aa84511ac7a29517 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:715ea3d186ce4717aa84511ac7a29517 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:715ea3d186ce4717aa84511ac7a295172021-11-04T19:00:26ZAnti-γ-Aminobutyric Acid Type β Receptor Antibody-Associated Encephalitis After 2 Cycles of Durvalumab Therapy in a Patient with Small Cell Lung Cancer: A Case Report1178-6930https://doaj.org/article/715ea3d186ce4717aa84511ac7a295172021-11-01T00:00:00Zhttps://www.dovepress.com/anti--aminobutyric-acid-type--receptor-antibody-associated-encephaliti-peer-reviewed-fulltext-article-OTThttps://doaj.org/toc/1178-6930Jiamo Li,1 Jianing Jiang,1,2 Jinyan Lv,1 Ru Zhang,1 Wenting Chen,1,2 Shiyi Li,1 Qianchen Jin,1 Gang Wang1,2 1Department of Medical Oncology, The Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning Province, People’s Republic of China; 2The Key Laboratory of Biomarker, High-Throughput Screening and Target Translation of Breast and Gastrointestinal Cancer, Dalian, Liaoning Province, People’s Republic of ChinaCorrespondence: Gang WangDepartment of Medical Oncology, The Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning Province, 116001, People’s Republic of ChinaTel/Fax +86-411-6289737Email 1136566004@qq.comAbstract: Anti-γ-aminobutyric acid type β receptor (anti-GABABR) antibody-associated encephalitis is a type of autoimmune encephalitis. According to current literature, its pathogenesis is reported to be closely related to tumor factors. However, diagnosis can be difficult because of the rarity of cases, limited clinical understanding, and a lack of specificity in clinical manifestation and imaging presentation. Clinical trials have demonstrated that immunotherapy can prolong the survival of patients with small cell lung cancer; however, in some cases, immunotherapy may induce anti-GABABR antibody-associated encephalitis. Patients who develop this encephalitis during immunotherapy often delay treatment because the cause is not clearly identified. In this study, we report a case of a 61-year-old man with a confirmed diagnosis of small cell lung cancer who had acute onset of cognitive impairment and seizures after two cycles of durvalumab (AstraZeneca UK Limited) combination chemotherapy. This reaction was initially considered as an immune-related adverse event (irAE) caused by durvalumab treatment, and the patient was eventually considered to have a paraneoplastic neurological disorder caused by the primary tumor. This report raises awareness of the symptoms of cognitive impairment and seizures in patients with small cell lung cancer, and the possible adverse events associated with immunotherapy. This case also highlights the importance of detecting anti-GABABR antibodies in patients with small cell lung cancer.Keywords: anti-GABABR antibody, autoimmune encephalitis, immunotherapies, small cell lung cancer, durvalumabLi JJiang JLv JZhang RChen WLi SJin QWang GDove Medical Pressarticleanti-gababr antibodyautoimmune encephalitisimmunotherapiessmall cell lung cancerdurvalumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENOncoTargets and Therapy, Vol Volume 14, Pp 5227-5236 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
anti-gababr antibody autoimmune encephalitis immunotherapies small cell lung cancer durvalumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
anti-gababr antibody autoimmune encephalitis immunotherapies small cell lung cancer durvalumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Li J Jiang J Lv J Zhang R Chen W Li S Jin Q Wang G Anti-γ-Aminobutyric Acid Type β Receptor Antibody-Associated Encephalitis After 2 Cycles of Durvalumab Therapy in a Patient with Small Cell Lung Cancer: A Case Report |
| description |
Jiamo Li,1 Jianing Jiang,1,2 Jinyan Lv,1 Ru Zhang,1 Wenting Chen,1,2 Shiyi Li,1 Qianchen Jin,1 Gang Wang1,2 1Department of Medical Oncology, The Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning Province, People’s Republic of China; 2The Key Laboratory of Biomarker, High-Throughput Screening and Target Translation of Breast and Gastrointestinal Cancer, Dalian, Liaoning Province, People’s Republic of ChinaCorrespondence: Gang WangDepartment of Medical Oncology, The Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning Province, 116001, People’s Republic of ChinaTel/Fax +86-411-6289737Email 1136566004@qq.comAbstract: Anti-γ-aminobutyric acid type β receptor (anti-GABABR) antibody-associated encephalitis is a type of autoimmune encephalitis. According to current literature, its pathogenesis is reported to be closely related to tumor factors. However, diagnosis can be difficult because of the rarity of cases, limited clinical understanding, and a lack of specificity in clinical manifestation and imaging presentation. Clinical trials have demonstrated that immunotherapy can prolong the survival of patients with small cell lung cancer; however, in some cases, immunotherapy may induce anti-GABABR antibody-associated encephalitis. Patients who develop this encephalitis during immunotherapy often delay treatment because the cause is not clearly identified. In this study, we report a case of a 61-year-old man with a confirmed diagnosis of small cell lung cancer who had acute onset of cognitive impairment and seizures after two cycles of durvalumab (AstraZeneca UK Limited) combination chemotherapy. This reaction was initially considered as an immune-related adverse event (irAE) caused by durvalumab treatment, and the patient was eventually considered to have a paraneoplastic neurological disorder caused by the primary tumor. This report raises awareness of the symptoms of cognitive impairment and seizures in patients with small cell lung cancer, and the possible adverse events associated with immunotherapy. This case also highlights the importance of detecting anti-GABABR antibodies in patients with small cell lung cancer.Keywords: anti-GABABR antibody, autoimmune encephalitis, immunotherapies, small cell lung cancer, durvalumab |
| format |
article |
| author |
Li J Jiang J Lv J Zhang R Chen W Li S Jin Q Wang G |
| author_facet |
Li J Jiang J Lv J Zhang R Chen W Li S Jin Q Wang G |
| author_sort |
Li J |
| title |
Anti-γ-Aminobutyric Acid Type β Receptor Antibody-Associated Encephalitis After 2 Cycles of Durvalumab Therapy in a Patient with Small Cell Lung Cancer: A Case Report |
| title_short |
Anti-γ-Aminobutyric Acid Type β Receptor Antibody-Associated Encephalitis After 2 Cycles of Durvalumab Therapy in a Patient with Small Cell Lung Cancer: A Case Report |
| title_full |
Anti-γ-Aminobutyric Acid Type β Receptor Antibody-Associated Encephalitis After 2 Cycles of Durvalumab Therapy in a Patient with Small Cell Lung Cancer: A Case Report |
| title_fullStr |
Anti-γ-Aminobutyric Acid Type β Receptor Antibody-Associated Encephalitis After 2 Cycles of Durvalumab Therapy in a Patient with Small Cell Lung Cancer: A Case Report |
| title_full_unstemmed |
Anti-γ-Aminobutyric Acid Type β Receptor Antibody-Associated Encephalitis After 2 Cycles of Durvalumab Therapy in a Patient with Small Cell Lung Cancer: A Case Report |
| title_sort |
anti-γ-aminobutyric acid type β receptor antibody-associated encephalitis after 2 cycles of durvalumab therapy in a patient with small cell lung cancer: a case report |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/715ea3d186ce4717aa84511ac7a29517 |
| work_keys_str_mv |
AT lij antigammaaminobutyricacidtypebetareceptorantibodyassociatedencephalitisafter2cyclesofdurvalumabtherapyinapatientwithsmallcelllungcanceracasereport AT jiangj antigammaaminobutyricacidtypebetareceptorantibodyassociatedencephalitisafter2cyclesofdurvalumabtherapyinapatientwithsmallcelllungcanceracasereport AT lvj antigammaaminobutyricacidtypebetareceptorantibodyassociatedencephalitisafter2cyclesofdurvalumabtherapyinapatientwithsmallcelllungcanceracasereport AT zhangr antigammaaminobutyricacidtypebetareceptorantibodyassociatedencephalitisafter2cyclesofdurvalumabtherapyinapatientwithsmallcelllungcanceracasereport AT chenw antigammaaminobutyricacidtypebetareceptorantibodyassociatedencephalitisafter2cyclesofdurvalumabtherapyinapatientwithsmallcelllungcanceracasereport AT lis antigammaaminobutyricacidtypebetareceptorantibodyassociatedencephalitisafter2cyclesofdurvalumabtherapyinapatientwithsmallcelllungcanceracasereport AT jinq antigammaaminobutyricacidtypebetareceptorantibodyassociatedencephalitisafter2cyclesofdurvalumabtherapyinapatientwithsmallcelllungcanceracasereport AT wangg antigammaaminobutyricacidtypebetareceptorantibodyassociatedencephalitisafter2cyclesofdurvalumabtherapyinapatientwithsmallcelllungcanceracasereport |
| _version_ |
1718444656380870656 |